MARKET

BRNS

BRNS

Barinthus Biotherapeutics plc
NASDAQ
0.8670
-0.0330
-3.67%
Closed 15:55 05/09 EDT
OPEN
0.9250
PREV CLOSE
0.9000
HIGH
0.9250
LOW
0.8670
VOLUME
9.13K
TURNOVER
--
52 WEEK HIGH
2.450
52 WEEK LOW
0.6400
MARKET CAP
34.97M
P/E (TTM)
-0.5290
1D
5D
1M
3M
1Y
5Y
1D
Barinthus Biotherapeutics GAAP EPS of -$0.49 misses by $0.12
Seeking Alpha · 3d ago
Barinthus Biotherapeutics Reports Q1 2025 Financial Results
TipRanks · 3d ago
Analysts Offer Insights on Healthcare Companies: US Physical Therapy (USPH) and Barinthus Biotherapeutics (BRNS)
TipRanks · 4d ago
Barinthus Biotherapeutics Q1 EPS $(0.49) Misses $(0.36) Estimate
Benzinga · 4d ago
Barinthus Biotherapeutics Restructures Leadership with New CFO
TipRanks · 4d ago
Barinthus Biotherapeutics reports Q1 EPS (49c), consensus (36c)
TipRanks · 4d ago
Weekly Report: what happened at BRNS last week (0428-0502)?
Weekly Report · 6d ago
Weekly Report: what happened at BRNS last week (0421-0425)?
Weekly Report · 04/28 10:20
More
About BRNS
Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases and autoimmunity. Its pipeline, built around platform technologies; viral vector-based, consists of ChAdOx and MVA, and synthetic, consisting of SNAP-Tolerance Immunotherapy (SNAP-TI). These platforms help to develop antigen-specific immunotherapeutic candidates designed to optimize the disease fighting capabilities of T cells and guide them towards a healthy balance. It is focused on developing two key product candidates that harness its viral vector and synthetic platform technologies. These include VTP-300, a Phase II immunotherapeutic candidate designed as a potential component of a functional cure for chronic hepatitis B virus infection utilizing ChAdOx/MVA, and VTP-1000, its autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease.

Webull offers Barinthus Biotherapeutics PLC - ADR stock information, including NASDAQ: BRNS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BRNS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BRNS stock methods without spending real money on the virtual paper trading platform.